Author:
Yerushalmi Yaara,Shem-Tov Noga,Danylesko Ivetta,Canaani Jonathan,Avigdor Abraham,Yerushalmi Ronit,Nagler Arnon,Shimoni Avichai
Abstract
Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with AML/ MDS relapsing after a first transplant (HSCT1). However, patients allocated to HSCT2 may be a selected group with better prognosis and the added efficacy of HSCT2 is not well established. We retrospectively analyzed 407 consecutive patients with relapsed AML/MDS after HSCT1. Sixty-two patients had HSCT2 (15%) and 345 did not. The 2-year cumulative incidence rates of non-relapse mortality and relapse after HSCT2 were 26% (95% CI, 17-39%) and 50% (95% CI, 39-65%), respectively. The 5-year overall survival (OS) rates were 25% (95% CI, 14-36%) and 7% (95% CI, 4-10%) in the HSCT2 and no-HSCT2 groups, respectively. Multivariate-analysis identified female gender (HR 0.31, P=0.001), short remission duration after HSCT1 (HR 2.31, P=0.05), acute GVHD after HSCT1 (HR 2.27, P=0.035), HSCT2 from haplo-identical (HR 13.4, P=0.001) or matched-unrelated donor (HR 4.53, P=0.007) and relapse after HSCT1 in earlier years (HR 2.46, P=0.02) as factors predicting OS after HSCT2. Multivariate-analysis of all patients including HSCT2 entered as time-dependent variable identified relapse within 6 months after HSCT1 (HR 2.32, P
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献